Zura Bio posts corporate overview highlighting tibulizumab dual IL-17/BAFF bispecific program in Phase 2 development

Reuters2026/08/11 11:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zura Bio highlighted tibulizumab, a bispecific antibody designed to inhibit IL-17 and BAFF across multiple immune-mediated diseases.
Phase 2 hidradenitis suppurativa topline data targeted for Q4 2026; systemic sclerosis topline data expected in 1H 2027.
Polymyalgia rheumatica Phase 2 study planned to start by year-end 2026.
Phase 1/1b program dosed 78 participants; median trough target engagement exceeded 98% for IL-17 and BAFF at 300 mg Q4W.
Cash runway projected through at least year-end 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zura Bio posts corporate overview highlighting tibulizumab dual IL-17/BAFF bispecific program in Phase 2 development

You may also like

Crypto prices